John Celebi
Chief Executive Officer bei SENSEI BIOTHERAPEUTICS, INC.
Vermögen: 110 691 $ am 31.03.2024
Profil
John K.
Celebi is currently the President, Chief Executive Officer & Director at Panacea Pharmaceuticals, Inc. and Sensei Biotherapeutics, Inc. He is also a Director at Egle Therapeutics SAS.
Previously, he held positions as the Director-Business Development at Cyclis Pharmaceuticals, Inc., Principal at Biogen MA, Inc., Senior Financial Analyst-New Ventures at Agilent Technologies, Inc., Research Associate at Tularik, Inc., Chief Operating Officer at X4 Pharmaceuticals, Inc., VP-Business Development & New Product Planning at ArQule, Inc., and Chief Business Officer at Igenica Biotherapeutics, Inc. Mr. Celebi holds an MBA from Carnegie Mellon University and an undergraduate degree from the University of California San Diego.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.02.2024 | 105 420 ( 0,42% ) | 110 691 $ | 31.03.2024 |
Aktive Positionen von John Celebi
| Unternehmen | Position | Beginn |
|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Chief Executive Officer | 01.02.2018 |
Panacea Pharmaceuticals, Inc.
 Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | Chief Executive Officer | - |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Director/Board Member | - |
Ehemalige bekannte Positionen von John Celebi
| Unternehmen | Position | Ende |
|---|---|---|
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Chief Operating Officer | 01.02.2018 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01.01.2016 |
| ARQULE, INC. | Corporate Officer/Principal | 01.01.2011 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Cyclis Pharmaceuticals, Inc.
 Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyclis Pharmaceuticals, Inc. researches and develops small molecule drugs for the treatment of cancer. It is engaged in the discovery and development of novel drugs which are based on the restoration and activation of cellular checkpoints. The company is headquartered in Norwood, MA. | Corporate Officer/Principal | - |
Ausbildung von John Celebi
| Carnegie Mellon University | Masters Business Admin |
| University of California San Diego | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AGILENT TECHNOLOGIES, INC. | Health Technology |
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cyclis Pharmaceuticals, Inc.
Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyclis Pharmaceuticals, Inc. researches and develops small molecule drugs for the treatment of cancer. It is engaged in the discovery and development of novel drugs which are based on the restoration and activation of cellular checkpoints. The company is headquartered in Norwood, MA. | Health Technology |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | Health Technology |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Commercial Services |
